November 03, 2022
Video
Lajos Pusztai, MD, DPhil, discusses the promise of neoadjuvant immunotherapy trials including the KEYNOTE-522 trial evaluating pembrolizumab plus chemotherapy in patients with triple-negative breast cancer.
October 27, 2022
Video
Lajos Pusztai, MD, DPhil, discusses key takeaways from analysis of the KEYNOTE-522 clinical trial of pembrolizumab plus chemotherapy in the neoadjuvant or adjuvant setting for patients with triple-negative breast cancer.
June 16, 2022
Video
Lajos Pusztai, MD, DPhil, discusses multiple analyses of the phase 3 KEYNOTE-522 clinical trial of pembrolizumab plus chemotherapy administered in the neoadjuvant or adjuvant setting to patients with triple-negative breast cancer versus placebo plus chemotherapy.
October 03, 2016
Video
Lajos Pusztai, MD, professor of medicine, chief of Breast Medical Oncology, Yale Cancer Center, and Co-Director, Yale Cancer Center Genetics, Genomics and Epigenetics Program, discusses the potential role of immunotherapy in the management of breast cancer.